Aratana Therapeutics (NASDAQ: PETX) and Phibro Animal Health Corporation (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitabiliy, risk, institutional ownership, valuation, dividends and earnings.
Volatility & Risk
Aratana Therapeutics has a beta of 3.43, suggesting that its stock price is 243% more volatile than the S&P 500. Comparatively, Phibro Animal Health Corporation has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
This table compares Aratana Therapeutics and Phibro Animal Health Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Phibro Animal Health Corporation||8.49%||54.68%||10.12%|
This is a summary of recent recommendations for Aratana Therapeutics and Phibro Animal Health Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Phibro Animal Health Corporation||2||2||2||0||2.00|
Aratana Therapeutics presently has a consensus price target of $10.40, indicating a potential upside of 43.25%. Phibro Animal Health Corporation has a consensus price target of $28.80, indicating a potential downside of 19.89%. Given Aratana Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Aratana Therapeutics is more favorable than Phibro Animal Health Corporation.
Valuation & Earnings
This table compares Aratana Therapeutics and Phibro Animal Health Corporation’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Aratana Therapeutics||$42.17 million||6.53||-$16.31 million||($0.75)||-9.68|
|Phibro Animal Health Corporation||$758.62 million||1.88||$116.09 million||$1.62||22.19|
Phibro Animal Health Corporation has higher revenue and earnings than Aratana Therapeutics. Aratana Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health Corporation, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
67.9% of Aratana Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Phibro Animal Health Corporation shares are owned by institutional investors. 5.2% of Aratana Therapeutics shares are owned by insiders. Comparatively, 48.1% of Phibro Animal Health Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Phibro Animal Health Corporation pays an annual dividend of $0.40 per share and has a dividend yield of 1.1%. Aratana Therapeutics does not pay a dividend. Phibro Animal Health Corporation pays out 24.7% of its earnings in the form of a dividend.
Phibro Animal Health Corporation beats Aratana Therapeutics on 8 of the 15 factors compared between the two stocks.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
Phibro Animal Health Corporation Company Profile
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. The Company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. The Company’s Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company’s MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285491/head-to-head-analysis-aratana-therapeutics-nasdaqpetx-and-phibro-animal-health-corporation-pahc.html
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.